CANbridge Announces that Velaglucerase-beta for Injection Successfully Passed the Pre-approval inspection and Pre - marketing GMP Compliance Inpection for the Pilot Biological Product of Divided manufacturing
CANbridge Announces Expansion of Livmarli® Label to Include ALGS Patients as Young as 2 Months in Taiwan
CANbridge Announces Marketing Approval of Livmarli® in Taiwan for the Treatment of Cholestatic Pruritus in PFIC Patients
CANbridge and Scriptr Global Announce Publication in the Journal Science Reporting the Discovery of the StitchR™ RNA Assembly Technology and its Application for the Treatment of Muscular Dystrophies
CANbridge Pharmaceuticals CAN103 New Drug Application (NDA), for Gaucher disease, Accepted by China’s National Medical Products Administration
CANbridge Pharmaceuticals Successfully Obtains Drug Manufacturing License Type B Certificate
CANbridge Pharmaceuticals’ CAN103 for Gaucher Disease Granted Priority Review Status by CDE of the NMPA
CANbridge Reports Positive Topline Data from CAN103 Pivotal Trial for Gaucher Disease in China, Plans NDA Filing in Q4 2024
CANbridge’s Livmarli Is Recommended in The “ Expert Consensus on Diagnosis and Treatment of ALGS Associated Liver Disease” Published By The Chinese Journal of Pediatrics
CANbridge Announces Last Patient Last Visit in CAN103 Phase 2/Registration Trial for Gaucher Disease
CANbridge Announces Expansion of LIVMARLI® Label to Include Patients as Young as 3 Months in China
CANbridge Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2023
CANbridge and PUMCH announced the establishment of PUMCH- CANbridge Genetic Defect Rare Disease Innovation and Translation Base
Livmarli mentioned as a case study The Policy Address highlights Hong Kong's strengths in research and development, emphasizing its capcity to independently approve new drugs Rare disease drugs will receive significant benefits
Foundation consolidated over time and for a rosy future | 2023 China Conference on Rare Diseases closed successfully
CANbridge Pharmaceuticals to Present Fabry Disease Gene Therapy Abstract at ESGCT 30th Annual Congress
CANbridge Announces NDA Acceptance of CAN108 (邁芮倍®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) by China’s National Medical Products Administration
CANbridge Announces Full Enrollment Reached in the Core Part of The CAN103 Phase 2 Trial for Gaucher Disease in China
CANbridge Announces Marketing Approval of CAN108 (邁芮倍®/LIVMARLI®) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (ALGS) - LIVMARLI is the First and Only Treatment Approved in Taiwan for Cholestatic Pruritus in ALGS - LIVMARLI is approved for Cholestatic Pruritus in ALGS in the US, Canada, Europe, Mainland China, and other regions globally
CANbridge Announces Marketing Approval of CAN108 (LIVMARLI®) in Hong Kong for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (ALGS) - LIVMARLI is the First and Only Treatment Approved in Hong Kong for Cholestatic Pruritus in ALGS - LIVMARLI is approved for Cholestatic Pruritus in ALGS in the United States, Canada, Europe, Mainland China and other regions globally
CANbridge Pharmaceuticals Fabry Disease Gene Therapy Abstract Accepted by ESGCT 30th Annual Congress Presentation
Policy News | “Second List of Rare Diseases” Published: A Pivotal Milestone in China’s Healthcare with 86 Rare Diseases Listed
CANbridge to Participate in Two Investor Conferences in September
CANbridge Announces Interim Financial Results and Corporate Updates for the Six Months Ended June 30, 2023
CANbridge to Continue CAN008 Phase 2 Trial in Glioblastoma Multiforme (GBM) in China Based on Interim Analysis of Independent Data Monitoring Committee
CANbridge Reports Positive Preliminary Data in the Omoprubart (CAN106) Phase 1b Trial in Paroxysmal Nocturnal Hemoglobinuria (PNH) in China -Promising Efficacy and Safety with Four-Week Extended Dosing -Data Shows Dose-Dependent Reduction of LDH and Increased Hemoglobin Levels that Demonstrate Clinically Meaningful Hemolysis Inhibition -CANbridge Plans to Advance to Pivotal Trial -CANbridge to Hold Investor Call
CANbridge Announces Marketing Approval of CAN108 (迈芮倍®/LIVMARLI®) in China for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome -LIVMARLI First and Only Treatment Approved in Mainland China for Cholestatic Pruritus in ALGS -CANbridge to Hold Investor Call
CANbridge to Participate in the Jefferies 2023 Global Healthcare Conference
CANbridge Announces Full Enrollment Reached in China Region of the Global LIVMARLI® (CAN108) EMBARK Phase 2 Study in Biliary Atresia
CANbridge and UMass Chan Medical School Spinal Muscular Atrophy Gene Therapy (CAN203) Improves Lifespan and Motor Function in Mice When Administered via Intracerebroventricular Injection -Data Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
CANbridge Pharmaceuticals Appoints Jason West Vice President, Head of Gene Therapy Research
CANbridge-UMass Chan Medical School Spinal Muscular Atrophy Gene Therapy Animal Data to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting -Novel Second-Generation SMA Gene Therapy Rescues Motor Function in Mice, Outperforms Benchmark Therapy
CANbridge Pharmaceuticals Spinal Muscular Atrophy Gene Therapy Abstract Accepted for Presentation at the American Society for Gene and Cell Therapy Annual Meeting
CANbridge Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2022
CANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme (GBM) in China Reaches Full Enrollment -Recent CAN008 Phase 1 Follow-Up Data Showed 67% 5-Year Overall Survival in High-Dose Cohort, Reported at ESMO Sarcoma and Rare Cancers
Long-Term Data from CANbridge Pharmaceuticals CAN008 Phase 1/2 Trial in Glioblastoma Multiforme Shows 67% Five-Year Overall Survival Rate Compared to 8.2% in Institutional Database -Data to be Presented at the ESMO Sarcoma and Rare Cancers Annual Congress -83% overall survival at two years vs. 34.3% OS from institutional database -17.95 months median progression-free survival vs. 5.8 months PFS in historical group
CANbridge Pharmaceuticals Announces CAN008 Phase 1/2 Glioblastoma Multiforme Abstract Accepted by the ESMO Sarcoma and Rare Cancers Congress
CANbridge Named to South Reviews “2022 Annual List of Chinese Social Values”
Article from Cloud-based Medicine Studio | A national authoritative medical organization for rare diseases will be established, and the second list of rare diseases will be updated
(attachments: the first list and the national reimbursement drug list)
First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 2 Trial for the Treatment of Gaucher Disease in China
CANbridge Congratulates Apogenix on First Patient Dosed in Asunercept (CAN008) Phase 3 Trial for the Treatment of COVID-19 -CANbridge holds exclusive rights for the development of CAN008 for any indication in Greater China -CAN008 currently in Phase 2 trial for the treatment of glioblastoma multiforme in China
CANbridge Consolidates Gene Therapy Portfolio -Secures Exclusive Global Rights to Potentially Best-in-Class Spinal Muscular Atrophy Gene Therapy from UMass Chan Medical School -Completes Technology Transfer of Two Gene Therapies for Lysomal Storage Diseases
CANbridge Congratulates Mirum on EU Marketing Approval for Maralixibat/LIVMARLI® to Treat Cholestatic Pruritis in Rare Liver Disease, Alagille Syndrome -Together with recent positive topline Phase 3 data in progressive familial intrahepatic cholestasis (PFIC), approval underscores maralixibat potential as promising new rare liver disease treatment -CANbridge holds exclusive Greater China license to maralixibat (CAN108) in liver diseases, China part of global trial ongoing in biliary atresia (BA）
CANbridge Pharmaceuticals Announces Orphan Drug Designation Granted to CAN 106 for the Treatment of Myasthenia Gravis
Article from PhIRDA｜Bi Jingquan: To encourage the R&D of drugs for rare diseases, we need to study and formulate special policies that conform to the characteristics of rare diseases
CANbridge Announces Encouraging Development in Maralixibat/LIVMARLI in Rare Liver Disease - Congratulates Mirum on Positive Topline Phase 3 Data in progressive familial intrahepatic cholestasis (PFIC) - CANbridge holds exclusive Greater China license to maralixibat (CAN108) in liver diseases, China trial ongoing in biliary atresia (BA)
CANbridge-UMass Chan Medical School Gene Therapy Research in Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 29th Annual Congress
CANbridge Pharmaceuticals to Participate in Upcoming Investor Conferences Gene Therapy Data to be Presented at the European Society of Gene and Cell Therapy
CANbridge Pharmaceuticals Data on CAN106, to be Presented at Two Conferences Complement C5 Antibody, CAN106, in Phase 1b/2 China Trial in Paroxysmal Nocturnal Hemoglobinuria (PNH)
CANbridge Pharmaceuticals to Participate in Two Investor Conferences in September
CANbridge Pharmaceuticals Presented at the Jefferies Asia Forum
CANbridge Announces Financial Results and Corporate Updates for Six Months Ended June 30, 2022
First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 1/2 Trial for the Treatment of Gaucher Disease in China
First Patient Dosed in CAN108 (Maralixibat) EMBARK Phase 2 Study in Biliary Atresia in China - China Study is Part of Global EMBARK Study
CANbridge Forms Scientific Advisory Board to Guide Global Development of CAN106 in Complement-mediated Diseases
CANbridge Appoints Industry Leader Edward Hu to the Board
CANbridge CAN106 Phase 1 Data Presented at the European Hematology Association 2022 Congress
CANbridge Pharmaceuticals to Present at the Jefferies Global Healthcare Conference 2022
CANbridge Pharmaceuticals to Participate in the Morgan Stanley Virtual China Summit 2022
CANbridge-UMass Chan Medical School Gene Therapy Research Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting First Study from CANbridge UMass Collaboration Shows Novel Gene Therapy Holds Promise for Spinal Muscular Atrophy Clinical Applications
CANbridge to Present CAN106 Phase 1 Data at the European Hematology Association 2022 Congress
Major Breakthrough | China’s National Medical Products Administration potentially to grant new rare disease drugs market exclusivity for up to seven years
CANbridge Pharmaceuticals Appoints Pauline Li as Senior Vice President of Clinical Development and Operations
CANbridge-UMass Chan Medical School Gene Therapy Research to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting First Study from the CANbridge UMass Chan Medical School Rare Disease Gene Therapy Research Collaboration
CANbridge Pharmaceuticals CAN108 New Drug Application/Orphan Drug Registration (NDA/ORD) for Alagille Syndrome Accepted by the Taiwan Food and Drug Administration
First Patient Dosed in CAN106 Phase 1b/2 Trial for Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
CANbridge Announces Financial Results and Corporate Updates for the Twelve Months Ended December 31, 2021
CANbridge Announces Approval of CAN108for Rare Liver Disease, Alagille Syndrome, Under the Early and Pilot Implementation Policy in Boao Lecheng International Medical Tourism Pilot Zone
CANbridge Pharmaceuticals Appoints Dr. Lan Hu as New Independent Director
CANbridge Reports Positive Top-Line CAN106 Phase 1 Data Receives Approval to Treat Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in Phase 1b/2 Trial in China Results Suggest Complete Blockade of Complement Function CAN106 Safe and Well-Tolerated
CANbridge Pharmaceuticals CAN108 New Drug Application (NDA), for Alagille Syndrome, Accepted by China’s National Medical Products Administration Priority Review Expected to be Granted
Chinese Red Cross Foundation’s Rare Disease Support Fund Officially Launched
CANbridge Pharmaceuticals Ltd Listed on Main Board of Hong Kong Stock Exchange
CANbridge and Peking Union Medical College Hospital Agree to Collaborate on Scientific Research for Rare Diseases
CANbridge Pharmaceuticals Enters into Duchenne Muscular Dystrophy Gene Therapy Research Agreement with University of Washington School of Medicine
First Patient Dosed in CANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme (GBM) in China
CANbridge Pharmaceuticals Enters into Exclusive Worldwide Research Collaboration and Licensing Agreement with Scriptr Global for Stitchr™ RNA Assembly Technology to Develop Gene Therapy Product Targeting Dystrophinopathies CANbridge to Have Exclusive Worldwide Rights to Product
CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease
CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Accepted by China’s National Medical Products Administration
CANbridge Pharmaceuticals CAN106 Investigational New Drug Application Approved in China for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
CANbridge Pharmaceuticals CEO, James Xue, Named as Termeer Foundation Mentor
Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China for Rare Liver Diseases
CANbridge Pharmaceuticals Announces Strategic Collaboration with LogicBio Therapeutics and Licenses to Gene Delivery and Editing Platforms
First Subject Dosed in CANbridge Pharmaceuticals CAN106 Trial for Treatment of Complement Dysregulation Diseases in Singapore
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration
CANbridge Pharmaceuticals Appoints General Manager of China
CANbridge Pharmaceuticals CAN106 Investigational New Drug Application Approved in Singapore for the Treatment of Complement Dysregulation Diseases
CANbridge Pharmaceuticals Completes $43 Million Series E Financing
CANbridge Pharmaceuticals Appoints Head of Global Research
CANbridge Pharmaceuticals Receives Chinese Marketing Approval for Hunterase® First Enzyme Replacement Therapy for Hunter Syndrome in China
CANbridge Pharmaceuticals Enters into Second Rare Disease Gene Therapy Research Agreement with UMass Medical School
CANbridge Pharmaceuticals Receives Marketing Approval for Nerlynx® (Neratinib) in Taiwan
CANbridge Pharmaceuticals Appoints Senior Vice President/Global Head of Business Development
CANbridge Pharmaceuticals Enters into Rare Disease Gene Therapy Research Agreement with UMass Medical School
CANbridge Pharmaceuticals Receives Marketing Approval for Nerlynx® (Neratinib) in China
CANbridge Pharmaceuticals Completes US$98 Million Series D Financing
Shanghai Foundation for Rare Disease Appoints CANbridge CEO, James Xue, Deputy Director General Sole Representative from the Pharmaceutical Industry
CANbridge Receives Hong Kong Department of Health Market Approval for Nerlynx®
CANbridge Pharmaceuticals’ Hunterase® Granted Priority Review by the Chinese National Medical Products Administration
CANbridge Pharmaceuticals Appoints Senior Vice President, Rare Disease Commercial Operations
CANbridge Pharmaceuticals Submits New Drug Application for Hunterase® for the Treatment of Hunter Syndrome in China
CANbridge Pharmaceuticals Appoints Chief Financial Officer and Interim Chief Medical Officer
CANbridge Pharmaceuticals and WuXi Biologics Expand Rare Disease Therapeutics Partnership
CANbridge Pharmaceuticals and GC Pharma Announce Greater China Licensing Agreement for Hunterase™ for Hunter Syndrome
CANbridge Pharmaceutical and WuXi Biologics Enter into Strategic Partnership for Rare Disease Therapeutics
CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) in China
CANbridge Life Sciences Appoints Chief Medical Officer
CANbridge Life Sciences Appoints Vice President of Clinical Development and Medical Affairs and Director of Quality Assurance
CANbridge Receives China Food and Drug Administration Approval for CAN002 as Cancer Adjuvant Therapy
CANbridge Receives Approval to Commence CAN008 Phase II/III Trial in Glioblastoma Multiforme (Gbm) in China
Industry Veteran Joins CANbridge Life Sciences Advisory Team
Puma Biotechnology and CANbridge Life Sciences Enter into Exclusive Licensing Agreement to Commercialize Nerlynx® (Neratinib) in Greater China
CANbridge Appoints Sunny Zhang as Vice President of Regulatory Affairs and Quality
CANbridge Life Sciences Submits Investigational New Drug Application for CAN017 Trial in Esophageal Squamous Cell Cancer (ESCC) in China
CANbridge Completes Patient Enrolment for Phase I Clinical Trial of CAN008 in Treatment of Glioblastoma Multiforme in Taiwan
CAN008 Injection for the Treatment of Gbm China Taiwan Phase I Data Releasing
James Xue is Appointed to Leadership and Development Council Member
CANbridge Life Sciences Appoints Chief Business Officer Will Head First US Office
CANbridge Congratulates Apogenix APG101 Receiving Ema “Prime” Designation
CANbridge Submits Ind Application for CAN008 PHII/III Trial in GBM in China
James Xue, Founder and CEO of CANbridge, Present at 2017 China GCP Conference
James Xue, Founder and CEO of CANbridge, Present at 2017 Boston CEO Conference
CANbridge Life Sciences Raises $25 Million in Series B Round Led by Lapam Capital
CANbridge Life Sciences and Amoy Diagnostics Announced that They Have Entered into a Strategic Partnership to Develop a Companion Diagnostic Assay for Canbridge’s Lead Candidate, CAN008, a Fully Human FC Fusion Protein.
CANbridge Life Sciences Awarded “Deal of the Year 2016 ”by China Healthcare Investment Conference for License of Cancer Candidate from AVEO
First Patient Dosed in CANbridge’s CAN-008 Phase I/II Trial in Newly-diagnosed Glioblastoma Multiforme in Taiwan First CANbridge Clinical Trial
CANbridge Signs Agreement with Boehringer Ingelheim to Manufacture Inhibitory Antibody,CAN-017,for Esophageal Squamous Cell Cancer
CANbridge’s CAN-008 Approved for Phase I/II Trial in Newly-Diagnosed Glioblastoma Multiforme in Taiwan
CANbridge Appoints Dr. Huai Zhong Hu as Vice President of Preclinical Development
CANbridge Life Sciences ltd. Elected to be a Member of Phirda
James Xue, Founder and CEO of CANbridge, Present at 2016 Boston CEO Conference
CANbridge Submits Investigational New Drug Application to Taiwan Food and Drug Administration for CAN-008 Phase I/II Trial in Glioblastoma Selects WuXi Biologics to Manufacture CAN-008 for the China Market
AVEO and CANbridge Life Sciences Announce Exclusive Licensing Agreement for AV-203 Outside of North America
CANbridge Completes Chinese Glioblastoma Biomarker Study for Lead Candidate, CAN008 Plans to Initiate Phase I/II Trial in Taiwan in 2016
James Xue,Founder and CEO of CANbridge,to Present at 2016 East West CEO Conference
CANbridge Appoints Mark A. Goldberg as Acting Chief Medical Officer Raises Additonal Capital in Series a Plus Round
CANbridge Acquires License for Apogenix’s APG101 Onco-immunotherapy in Glioblastoma for China
CANbridge Life Sciences, Inc. Joins the Medtech Group
CANbridge Life Sciences Ceo,James Xue, Presenting at Cancer Advanced Boston and Boston CEO
James Xue, Founder and CEO of CANbridge, to Present at 2015 East West CEO Conference
CANbridge Life Sciences Raises $10 Million in Series a Round Led by Qiming Venture Partners
James Xue, Founder and CEO of CANbridge to Attend Cancer Advance Boston Conference
CANbridge Life Sciences and EUSA Pharma form Agreement to Commericialize Caphosol® in China
CANbridge Certified Frontier Oncology Diagnosis & Treatment International Collaboration Base by Beijing Municipal Commission of Science and Technology
CANbridge Featured in Biocentury
James Xue, Founder and CEO of CANbridge Recognized by “Chaoyang Phoenix High-caliber Overseas Talents 2013”
CANbridge to Present at Biotech Showcase™ 2014
CANbridge CEO Featured at Peking University Alumni Forum
CANbridge Certified Golden Seed Enterprise by Administrative Committee of Zhongguancun Science Park
An In-depth Interview with James Xue, CEO of CANbridge, by Pharmatimes
CANbridge-azaya Deal Featured in Bioworld Today
CANbridge Life Sciences Announces Advisory Board Memembers
CANbridge Enters Into Agreement with Azaya to Develop Anti-cancer Drug ATI-1123